2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
This program provides coverage of the 2018 ASCO annual meeting with summary slidesets and expert analyses of key results in gastrointestinal cancers, gynecologic cancers, skin cancer, cancer immunotherapy, genitourinary cancers, hematologic malignancies, breast cancer, and lung cancer.

Hematologic Malignancies

Capsule Summary Slidesets

Extended follow-up of this pivotal phase II trial suggests 3-month response to axi-cel may be prognostic of long-term remissions.

Released: June 5, 2018

Ivosidenib produced durable responses in heavily pretreated patients with relapsed/refractory IDH1-mutated AML.

Released: June 4, 2018

This CD22-targeted antibody–drug conjugate induced deep and durable responses in a heavily pretreated patient population with HCL.

Released: June 5, 2018

Preliminary findings suggest venetoclax plus decitabine or azacitidine is well tolerated with deep, durable responses in elderly patients with previously untreated AML.

Released: June 7, 2018

Retrospective analysis suggests that sequential use of blinatumomab and HSCT may benefit patients with BCP-ALL, particularly in younger patients.

Released: June 8, 2018

Lenalidomide plus rituximab did not improve CR rate or PFS over chemotherapy plus rituximab but was associated with lower rates of neutropenia and febrile neutropenia.

Released: June 6, 2018

Acalabrutinib monotherapy yielded a 93% ORR across cohorts with durable responses and a favorable safety profile.

Released: June 11, 2018

Early results show promising clinical responses and MRD clearance with combination first-line treatment in CLL with ibrutinib and venetoclax.

Released: June 6, 2018

Median PFS and ORR significantly improved with once- vs twice-weekly dosing of carfilzomib + dexamethasone in patients with relapsed/refractory multiple myeloma.

Released: June 7, 2018

The addition of pomalidomide to bortezomib and low-dose dexamethasone extends PFS vs bortezomib and low-dose dexamethasone alone in patients with relapsed/refractory multiple myeloma who have previously received lenalidomide.

Released: June 3, 2018

Daratumumab with carfilzomib and dexamethasone was well tolerated and active in patients with lenalidomide-refractory relapsed multiple myeloma.

Released: June 3, 2018

Planned interim analysis of phase III iNNOVATE study shows significant improvements in PFS with ibrutinib plus rituximab vs rituximab alone in patients with Waldenström macroglobulinemia.

Released: June 4, 2018

VenKd was well tolerated with promising response rates in R/R MM, including both high-risk and standard-risk patients, in a phase II trial.

Released: June 4, 2018

At active doses, bb2121 induced deep responses independent of BCMA expression and was associated with predominantly low-grade and manageable toxicities.

Released: June 4, 2018

Twice-weekly 56-mg/m2 carfilzomib showed similar PFS and OS but higher VGPR rate vs 27-mg/m2 carfilzomib in patients with relapsed/refractory multiple myeloma.

Released: June 11, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings